Neoplastic meningitis epidemiology and demographics: Difference between revisions
(Mahshid) |
No edit summary |
||
Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
===Prevalence=== | ===Prevalence=== | ||
Neoplastic meningitis occurs in approximately 3-5% of patients with solid tumor, 5-15% of patients with leukemia, and 1-2% of patients with primary brain tumors.<ref name="GleissnerChamberlain2006">{{cite journal|last1=Gleissner|first1=Beate|last2=Chamberlain|first2=Marc Charles|title=Neoplastic meningitis|journal=The Lancet Neurology|volume=5|issue=5|year=2006|pages=443–452|issn=14744422|doi=10.1016/S1474-4422(06)70443-4}}</ref><ref name=epidemiologynm2>Hayat, M. A. Brain metastases from primary tumors : epidemiology, biology, and therapy. London: Elsevier/Academic Press, 2014. Print.| url=https://books.google.com/books?id=IloXAwAAQBAJ&pg=PA43&lpg=PA43&dq=leptomeningeal+carcinomatosis+is+present+in+1-5%25+of+patients+with+solid+tumors,+5-15%25+of+patients+with+leukemia,+and+1-2%25+of+patients+with+primary+brain+tumors.&source=bl&ots=ehEaDBCT5f&sig=vvSxdxDjNMBe0CdCP6fEcMaYJqU&hl=en&sa=X&ved=0ahUKEwi2ueuw37bKAhUG8j4KHWUUCoIQ6AEILTAC#v=onepage&q=leptomeningeal%20carcinomatosis%20is%20present%20in%201-5%25%20of%20patients%20with%20solid%20tumors%2C%205-15%25%20of%20patients%20with%20leukemia%2C%20and%201-2%25%20of%20patients%20with%20primary%20brain%20tumors.&f=false. Accessed on January 19, 2016</ref> | Neoplastic meningitis occurs in approximately 3-5% of patients with solid tumor, 5-15% of patients with leukemia, and 1-2% of patients with primary brain tumors.<ref name="GleissnerChamberlain2006">{{cite journal|last1=Gleissner|first1=Beate|last2=Chamberlain|first2=Marc Charles|title=Neoplastic meningitis|journal=The Lancet Neurology|volume=5|issue=5|year=2006|pages=443–452|issn=14744422|doi=10.1016/S1474-4422(06)70443-4}}</ref><ref name=epidemiologynm2>Hayat, M. A. Brain metastases from primary tumors : epidemiology, biology, and therapy. London: Elsevier/Academic Press, 2014. Print.| url=https://books.google.com/books?id=IloXAwAAQBAJ&pg=PA43&lpg=PA43&dq=leptomeningeal+carcinomatosis+is+present+in+1-5%25+of+patients+with+solid+tumors,+5-15%25+of+patients+with+leukemia,+and+1-2%25+of+patients+with+primary+brain+tumors.&source=bl&ots=ehEaDBCT5f&sig=vvSxdxDjNMBe0CdCP6fEcMaYJqU&hl=en&sa=X&ved=0ahUKEwi2ueuw37bKAhUG8j4KHWUUCoIQ6AEILTAC#v=onepage&q=leptomeningeal%20carcinomatosis%20is%20present%20in%201-5%25%20of%20patients%20with%20solid%20tumors%2C%205-15%25%20of%20patients%20with%20leukemia%2C%20and%201-2%25%20of%20patients%20with%20primary%20brain%20tumors.&f=false. Accessed on January 19, 2016</ref> | ||
===Prevalence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
===Case-fatality rate/Mortality rate=== | |||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
*The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | |||
*[Acute disease name] commonly affects [age group]. | |||
===Race=== | |||
*There is no racial predilection to [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
===Developed Countries=== | |||
===Developing Countries=== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 19:54, 13 May 2019
Neoplastic meningitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neoplastic meningitis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Neoplastic meningitis epidemiology and demographics |
Neoplastic meningitis epidemiology and demographics in the news |
Blogs on Neoplastic meningitis epidemiology and demographics |
Risk calculators and risk factors for Neoplastic meningitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Neoplastic meningitis occurs in approximately 3-5% of patients with solid tumor, 5-15% of patients with leukemia, and 1-2% of patients with primary brain tumors.[1][2]
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
Neoplastic meningitis occurs in approximately 3-5% of patients with solid tumor, 5-15% of patients with leukemia, and 1-2% of patients with primary brain tumors.[1][2]
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 Gleissner, Beate; Chamberlain, Marc Charles (2006). "Neoplastic meningitis". The Lancet Neurology. 5 (5): 443–452. doi:10.1016/S1474-4422(06)70443-4. ISSN 1474-4422.
- ↑ 2.0 2.1 Hayat, M. A. Brain metastases from primary tumors : epidemiology, biology, and therapy. London: Elsevier/Academic Press, 2014. Print.| url=https://books.google.com/books?id=IloXAwAAQBAJ&pg=PA43&lpg=PA43&dq=leptomeningeal+carcinomatosis+is+present+in+1-5%25+of+patients+with+solid+tumors,+5-15%25+of+patients+with+leukemia,+and+1-2%25+of+patients+with+primary+brain+tumors.&source=bl&ots=ehEaDBCT5f&sig=vvSxdxDjNMBe0CdCP6fEcMaYJqU&hl=en&sa=X&ved=0ahUKEwi2ueuw37bKAhUG8j4KHWUUCoIQ6AEILTAC#v=onepage&q=leptomeningeal%20carcinomatosis%20is%20present%20in%201-5%25%20of%20patients%20with%20solid%20tumors%2C%205-15%25%20of%20patients%20with%20leukemia%2C%20and%201-2%25%20of%20patients%20with%20primary%20brain%20tumors.&f=false. Accessed on January 19, 2016